QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma,Β modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
MASLD/MASH: Clinical and Economic Findings from 40-year Follow-Up Data
πππππ/ππππ: ππ₯π’π§π’πππ₯ ππ§π πππ¨π§π¨π¦π’π π
π’π§ππ’π§π π¬ ππ«π¨π¦ 40-π²πππ« π
π¨π₯π₯π¨π°-ππ© ππππ
On Tuesday December 10th, Quantifyβs Emilie Toresson Grip is one of three speakers at ISPORβs webinar on MASLD/ MASH following their BRIDGE-MASH study.
Moderated by Riku Ota, Global Payer Evidence Lead at Novo Nordisk, speakers Hannes HagstrΓΆm, Ying Shang and Emilie Toresson Grip will explore the findings of the BRIDGE-MASH study, assessing clinical and economic outcomes [β¦]
NORdic Dataset for aSThmA Research (NORDSTAR) – a Nordic research collaboration platform
Real-world evidence derived from data collected in routine clinical care is increasingly important for decision-makers in payer and regulatory environments.
Nordic health data has several characteristics that enable a globally unique research environment and thus can be used to create globally relevant evidence for decision makers.
We at Quantify are proud to be part of NORDSTAR β a multinational, three-party research collaboration with [β¦]
Quantify Research and Academia: Partners in Advancing Real-World Evidence (RWE)
How does Quantify Research as a consultant research organisation compare to academia when it comes to generating RWE?
Hereβs a quick look at the unique strengths of each β and why both are vital for healthcare innovation:
π Focus: High Quality Scientific Work with Different Applications
Quantify delivers tailored RWE studies and practical solutions for RWE generation, mostly partnering with pharma stakeholders. We adapt methods to [β¦]
Are Scandinavia and the Nordics the same?
As the number one provider of Nordic registry studies, Quantify sits at the heart of Scandinavia.
The Nordics typically refers to Northern European countries with similar history, culture and social structures.
They include Denmark, Finland, Iceland, Norway and Sweden plus some autonomous territories.
Their commonalities stretch far into the health care sector with universal access and centralized data records, enabling our renowned high-quality studies [β¦]